<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449578</url>
  </required_header>
  <id_info>
    <org_study_id>223HV103</org_study_id>
    <nct_id>NCT01449578</nct_id>
  </id_info>
  <brief_title>Dexpramipexole SAD/MAD Study</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled Ascending Dose Study of the Safety and Pharmacokinetics of Dexpramipexole in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knopp Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Knopp Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single&#xD;
      doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID&#xD;
      dexpramipexole in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical and clinical data to date support the exploration of doses of dexpramipexole&#xD;
      higher than 150 mg twice daily for their effectiveness in slowing the progression of ALS.&#xD;
      Exploration of doses of dexpramipexole higher than 150 mg twice daily is justified by&#xD;
      preclinical and clinical data that suggest that higher doses could potentially be more&#xD;
      effective in slowing the progression of ALS than the dose of dexpramipexole currently being&#xD;
      explored in Phase 3 studies (150 mg twice daily).&#xD;
&#xD;
      This is a Phase 1, single-center, blinded, randomized, placebo controlled, ascending-dose&#xD;
      study consisting of 2 parts; Part A (single-ascending dose [SAD]) and Part B (multiple&#xD;
      ascending dose [MAD]). The study will explore safety, tolerability, and pharmacokinetics of&#xD;
      single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300&#xD;
      mg BID dexpramipexole in healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability based on medical review of adverse events &amp; results of vital sign measurements, electrocardiogram (ECGs), physical examinations and clinical laboratory tests.</measure>
    <time_frame>Change from baseline to 11 Days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dexpramipexole pharmacokinetics time frame in plasma</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Part A, Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (SAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole single dose placebo (SAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (SAD Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole single dose placebo (SAD Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (SAD Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole single dose placebo (SAD Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole multiple dose (MAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole multiple dose placebo (MAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole multiple dose (MAD Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole multiple dose placebo (MAD Dose 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole</intervention_name>
    <description>Oral Tablet at varying doses</description>
    <arm_group_label>Part A, Treatment 1</arm_group_label>
    <arm_group_label>Part A, Treatment 2</arm_group_label>
    <arm_group_label>Part A, Treatment 3</arm_group_label>
    <arm_group_label>Part B, Treatment 1</arm_group_label>
    <arm_group_label>Part B, Treatment 2</arm_group_label>
    <other_name>BIIB050</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole Placebo</intervention_name>
    <description>Oral tablet at varying doses</description>
    <arm_group_label>Part A, Treatment 1 placebo</arm_group_label>
    <arm_group_label>Part A, Treatment 2 placebo</arm_group_label>
    <arm_group_label>Part A, Treatment 3 placebo</arm_group_label>
    <arm_group_label>Part B, Treatment 1 placebo</arm_group_label>
    <arm_group_label>Part B, Treatment 2 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must give written informed consent.&#xD;
&#xD;
          -  Adult males/females aged 18 to 55 years inclusive and between 19 and 30 kg/m2 body&#xD;
             mass index (BMI), inclusive at screening.&#xD;
&#xD;
          -  Subjects who are healthy as determined by prestudy medical history, physical&#xD;
             examination and 12-lead ECG.&#xD;
&#xD;
          -  Subjects of childbearing potential must practice effective contraception during the&#xD;
             study and be willing and able to continue contraception for 1 month (females) or 3&#xD;
             months (males) after their last dose of study treatment.&#xD;
&#xD;
          -  Normal systemic blood pressure defined as a systolic blood pressure of 90 to 140 mmHg&#xD;
             and a diastolic blood pressure of 50 to 90 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiovascular disease (e.g., hypertension, arrhythmia, heart failure, Long&#xD;
             QT Syndrome, or other conditions/diseases causing prolongation of the QT/QTc&#xD;
             interval).&#xD;
&#xD;
          -  A prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval&#xD;
             &gt;450 ms before study treatment administration) at screening, admission or pre-dose on&#xD;
             Day 1.&#xD;
&#xD;
          -  Any clinically important abnormalities in resting ECG that may interfere with the&#xD;
             interpretation of QTc interval changes at screening, admission or pre-dose on Day 1.&#xD;
&#xD;
          -  Prior exposure to dexpramipexole.&#xD;
&#xD;
          -  Treatment with pramipexole or any dopamine agonist within 1 year.&#xD;
&#xD;
          -  Treatment with another investigational drug or approved therapy for investigational&#xD;
             use within 30 days, or 5 half-lives (whichever is longer), or in follow up for any&#xD;
             other drug, biologic, or device study.&#xD;
&#xD;
          -  Currently active infection or serious infection (e.g., pneumonia, septicemia) within&#xD;
             the 2 months prior to Day -2 as determined by the Investigator.&#xD;
&#xD;
          -  Female subjects who are pregnant, currently breastfeeding, or attempting to conceive&#xD;
             during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

